{{Drugbox
| IUPAC_name = ''N''-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1''H''-indazole-3-carboxamide
| image = ADB-PINACA_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Schedule I
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1633766-73-0
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 86280478
| ChemSpiderID      = 29342129
| smiles            = CCCCCN1C2=CC=CC=C2C(=N1)C(=O)NC(C(=O)N)C(C)(C)C
| StdInChI          = 1S/C19H28N4O2/c1-5-6-9-12-23-14-11-8-7-10-13(14)15(22-23)18(25)21-16(17(20)24)19(2,3)4/h7-8,10-11,16H,5-6,9,12H2,1-4H3,(H2,20,24)(H,21,25)
| StdInChIKey       = FWTARAXQGJRQKN-UHFFFAOYSA-N

<!--Chemical data-->
| C=19 | H=28 | N=4 | O=2
| molecular_weight = 344.51 g/mol
}}

'''ADB-PINACA''' is a [[cannabinoid]] [[designer drug]] that is an ingredient in some [[synthetic cannabis]] products. It is a potent [[agonist]] of the [[CB1 receptor|CB<sub>1</sub> receptor]] and [[CB2 receptor|CB<sub>2</sub> receptor]] with [[EC50|EC<sub>50</sub>]] values of 0.52&nbsp;nM and 0.88&nbsp;nM respectively.<ref>{{cite journal | url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00112 | title=The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA |author1=Samuel D Banister |author2=Michael Moir |author3=Jordyn Stuart |author4=Richard C Kevin |author5=Katie E Wood |author6=Mitchell Longworth |author7=Shane M Wilkinson |author8=Corinne Beinat |author9=Alxendra S Buchanan |author10=Michelle Glass |author11=Mark Connor |author12=Iain S McGregor |author13=Michael Kassiou | journal=ACS Chemical Neuroscience |date=July 2015  | doi=10.1021/acschemneuro.5b00112 | pmid=26134475 | volume=6 | pages=1546–59}}</ref><ref>{{cite web | url = http://forendex.southernforensic.org/index.php/detail/index/1257 | title = ADB-PINACA | publisher = Forendex}}</ref> Like [[MDMB-FUBINACA]], this compound contains an amino acid residue of [[tert-leucine]].

==Side effects==

ADB-PINACA has been linked to multiple hospitalizations and deaths due to its use.<ref>{{cite news | title = CDC: 221 sickened by synthetic pot in Colorado | url = https://www.usatoday.com/story/news/nation/2013/12/12/synthetic-pot-colorado/4005257/ | publisher = USA Today | date = December 12, 2013}}</ref><ref>{{cite journal | url=http://www.jem-journal.com/article/S0736-4679%2814%2901425-5/abstract | title=A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA | author=Michael D. Schwartz | journal=Journal of Emergency Medicine |date=March 2015  | volume=48 | issue=5 | pages=573–580 | doi=10.1016/j.jemermed.2014.12.038 | pmid=25726258|display-authors=etal}}</ref><ref>{{cite journal | url=http://www.nejm.org/doi/full/10.1056/NEJMp1505328 | title=Synthetic Cannabinoid–Related Illnesses and Deaths |author1=Jordan Trecki |author2=Roy R. Gerona |author3=Michael D. Schwartz | journal=New England Journal of Medicine |date=July 2015  | volume=373 | issue=2 | pages=103–107 | doi=10.1056/NEJMp1505328 | pmid=26154784}}</ref>

==Legality==

ADB-PINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.<ref>{{cite web | url=http://www.cnb.gov.sg/Libraries/CNB_Newsroom_Files/CNB_NR_-_30_Apr_2015.sflb.ashx | title=CNB NEWS RELEASE | publisher=Central Narcotics Bureau (CNB) | date=30 April 2015 | accessdate=24 July 2015}}</ref>

In the United States, it is a [[Schedule I controlled substance]].<ref name=pmid24605391>{{cite journal | pmid=24605391 | journal = Fed Regist. | date = Feb 10, 2014 | volume = 79 | issue = 27 | pages = 7577–7582 | title = Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order }}</ref>

As of October 2015 ADB-PINACA is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-AB-PINACA]]
* [[5F-ADB]]
* [[5F-ADB-PINACA]]
* [[5F-AMB]]
* [[5F-APINACA]]
* [[AB-FUBINACA]]
* [[AB-CHFUPYCA]]
* [[AB-CHMINACA]]
* [[AB-PINACA]]
* [[ADB-CHMINACA]]
* [[ADB-FUBINACA]]
* [[ADBICA]]
* [[APICA]]
* [[APINACA]]
* [[MDMB-CHMICA]]
* [[PX-3]]
{{Div col end}}

==References==
{{reflist}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indazoles]]
[[Category:Indazolecarboxamides]]
[[Category:Tert-butyl compounds]]